Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Journal: The New England journal of medicine
Published: June 04, 2024
Isatuximab-dexamethasone-pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 31, 2024
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Journal: Lancet (London, England)
Published: January 21, 2020
In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019.
Journal: Blood cancer journal
Published: August 25, 2019
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 31, 2019
A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 12, 2017
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series.
Journal: Leukemia & lymphoma
Published: June 07, 2017
Last Updated: 09/26/2026